Dersleri yüzünden oldukça stresli bir ruh haline sikiş hikayeleri bürünüp özel matematik dersinden önce rahatlayabilmek için amatör pornolar kendisini yatak odasına kapatan genç adam telefonundan porno resimleri açtığı porno filmini keyifle seyir ederek yatağını mobil porno okşar ruh dinlendirici olduğunu iddia ettikleri özel sex resim bir masaj salonunda çalışan genç masör hem sağlık hem de huzur sikiş için gelip masaj yaptıracak olan kadını gördüğünde porn nutku tutulur tüm gün boyu seksi lezbiyenleri sikiş dikizleyerek onları en savunmasız anlarında fotoğraflayan azılı erkek lavaboya geçerek fotoğraflara bakıp koca yarağını keyifle okşamaya başlar
Reach Us +44 1223 790975


PZP: A Novel Biomarker For Early Alzheimer�s Disease? | 21911
ISSN: 2161-0460

Journal of Alzheimers Disease & Parkinsonism
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

PZP: A novel biomarker for early Alzheimer�s disease?

2nd International Conference on Alzheimers Disease and Dementia

Diana A T Nijholt

ScientificTracks Abstracts: J Alzheimers Dis Parkinsonism

DOI: 10.4172/2161-0460.S1.006

Alzheimer�s disease (AD) is characterized by a long presymptomatic phase in which damage to the brain is already occurring but clinical symptoms are not yet manifested. Diagnosis of AD is hampered by the lack of reliable biomarkers that predict early disease onset and/or progression in the general population. For use in large scale screening an ideal biomarker (or panel of biomarkers) should be measurable in non-invasively obtained biomaterial, e.g. blood. Here we used a discovery based proteomics approach to identify blood-based biomarkers for early AD in samples derived from the prospective Rotterdam Study cohort. We compared the serum proteome of presymptomatic AD cases with cases that remained cognitively healthy and identified 61 differentially expressed peptides, 9 of which were derived from the pan-protease inhibitor PZP. Absolute quantification using selected reaction monitoring assays confirmed increased levels of PZP in serum of presymptomatic AD cases versus controls. We hypothesized that increased PZP levels are derived from the brain and performed immunohistochemical analysis in post-mortem brain material. Increased PZP immunoreactivity was observed in the AD brain compared to controls and this correlated with Braak stage for disease severity. Further analysis indicated PZP was predominantly expressed in microglia and associated with amyloid plaques in the AD brain. We are currently validating PZP as a biomarker for early AD in additional study cohorts and investigating its role in AD pathophysiology. For the latter we are combining immunohistochemistry, laser capture microdissection and advanced mass spectrometry analysis.
Diana A T Nijholt obtained her PhD in 2012 from the University of Amsterdam on the unfolded protein response. She is currently working as a post-doctoral fellow in the group of Dr. T.M. Luider (Erasmus Medical Center, Rotterdam) with a primary focus on the discovery and validation of biomarkers for neurodegenerative diseases. She has extensive expertise in the mass spectrometry based analysis of tissue and body fluid samples.